1. Completed
Mainboard
Mainboard issue. Listed.
Source: IPO Guru Pro
Company information, issue size, price band, lot size, minimum investment, and the dates published for this issue.
Corona Remedies Limited is an Indian pharmaceutical company established in 2004, focused on developing and marketing a wide range of branded formulations. The company was founded by Chandrakant Patel, who brought extensive experience from the domestic pharma industry. Over the years, Corona Remedies has built a strong presence in therapeutic segments such as women’s healthcare, cardiology, diabetology, pain management and anti-infectives. The company operates with a customer-centric approach, emphasising quality, innovation and accessibility of medicines. It has developed a robust distribution network across India, supported by a large field force that engages with healthcare professionals and institutions. By focusing on niche and high-growth segments, the company has been able to strengthen its brand recall and expand its footprint in the competitive pharmaceutical market. The company’s product portfolio consists primarily of branded generic medicines, including tablets, capsules, syrups and injectables, catering to both acute and chronic therapies. Corona Remedies follows an asset-light business model, where manufacturing is largely outsourced to WHO-GMP certified third-party facilities while it focuses on marketing, branding and distribution. This allows the company to maintain flexibility and control costs while ensuring consistent product quality. Its strategy revolves around launching differentiated products, building strong doctor relationships and expanding into new therapeutic areas. With a steady focus on research-backed marketing and efficient supply chain management, Corona Remedies aims to sustain long-term growth and strengthen its position in the Indian pharmaceutical industry.
Current premium in rupees, the derived percentage, and the indicative price. History shows observed readings only. A missing premium is unavailable, not ₹0.
Grey Market Premium (GMP) is an unofficial market indicator and is not published by stock exchanges. Estimated listing values are illustrative, may change, and should not be considered a forecast or investment recommendation.
Indicative only. A GMP-implied price is not a guaranteed listing price.
Subscription is shown in times subscribed. A missing multiple stays unavailable. A published zero is 0x.
Last updated: Unavailable
Last updated: Unavailable
Source: IPO Guru Pro Data by IPO Guru
History retrieved: 05 Nov 2026, 5:45 PM IST
No day-wise subscription history is loaded. Missing days are left blank and are not plotted as zero.
Source: IPO Guru Pro. History retrieved 05 Nov 2026, 5:45 PM IST.
Revenue and profit are in rupees for each reporting period. Assets, liabilities, and ratios use the source unit when the statement includes them. Missing figures stay blank.
| Metric (Rs. Crore) | 30 jun 25 | 31 mar 25 | 31 Mar 24 |
|---|---|---|---|
| Revenue | 348.56 | 1,202.35 | 1,020.93 |
| OPM % | 24.29 | 23.32 | — |
| EBITDA | 71.80 | 245.91 | 161.19 |
| Net Profit |
Results may still be pending. Check Allotment opens the registrar allotment portal. You may need to select this IPO there. Sign-in is not required.
This is the actual change from the issue price to the listing price. It is separate from the unofficial GMP estimate. A missing price stays unavailable.
RHP, DRHP, and other links that passed the official address check. Unverified addresses are left out.
Data by IPO Guru · Updated
Corona Remedies IPO is attracting investor attention as the company operates in branded generic pharmaceuticals across key therapeutic segments in India. The company has a strong presence in women’s healthcare, cardiology, and dermatology. With consistent revenue growth and an expanding product portfolio, the IPO is expected to support future expansion and debt reduction. Investors are watching subscription levels and valuation before making investment decisions.
Ankur Kirtikumar Mehta, Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta
1. Completed
2. Completed
3. Completed
4. Completed
Refund
Demat credit
Unofficial grey-market premium in rupees. Missing observations are not connected and are not drawn as ₹0. This chart is not the listing gain.
High unavailable · Low unavailable
Tap a point for its rupee amount, percentage, and IST time. The table lists the same observations.
Source: IPO Guru Pro. History retrieved 05 Nov 2026, 5:45 PM IST.
| Observed (IST) | GMP (₹) | GMP % | Mark |
|---|---|---|---|
| 13 Jan 2026, 5:45 PM IST | ₹300 | +28.25% | None |
No intraday GMP history is loaded. Missing slots are not filled in.
High unavailable · Low unavailable
Source: IPO Guru Pro. History retrieved 05 Nov 2026, 5:45 PM IST.
| 46.20 |
| 149.43 |
| 90.50 |
| Debt | 106.65 | 62.70 | 134.14 |
| Assets | 1,012.38 | 929.86 | 830.58 |